J&J Pauses Enrollment In Trial Of AC Immune-Partnered Anti-Tau Immunotherapy

robot
Abstract generation in progress

Johnson & Johnson has paused enrollment in a trial for an anti-tau immunotherapy, developed in partnership with AC Immune. While new patient recruitment is halted, existing participants will continue to receive dosing. This decision comes after J&J’s anti-tau asset, Posdinemab, previously failed in a Phase II Alzheimer’s study.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin

Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)